A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report
Covid-19 Convalescent Plasma (CCP) was one of alternative therapy for Covid-19 patients. The use of convalescent plasma as an adjunct therapy must consider its efficacy, benefits, and risk, both for the patient and the donor. Convalescent Plasma was produced from purified human plasma. Convalescent...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Faculty of Medicine
2023-08-01
|
| Series: | JKKI (Jurnal Kedokteran dan Kesehatan Indonesia) |
| Online Access: | https://jurnal.uii.ac.id/JKKI/article/view/25589 |
| _version_ | 1827812144530325504 |
|---|---|
| author | Teguh Triyono Usi Sukorini Andri Christianalusi Sri Mulatsih Hans Vrielink |
| author_facet | Teguh Triyono Usi Sukorini Andri Christianalusi Sri Mulatsih Hans Vrielink |
| author_sort | Teguh Triyono |
| collection | DOAJ |
| description | Covid-19 Convalescent Plasma (CCP) was one of alternative therapy for Covid-19 patients. The use of convalescent plasma as an adjunct therapy must consider its efficacy, benefits, and risk, both for the patient and the donor. Convalescent Plasma was produced from purified human plasma. Convalescent Plasma was a passive immunity which provide active antibodies. CCP give immunity to the patient through the transfusion of a survivor’s antibodies. We were reporting a case of male CCP donor with long existence of SARS-Cov-2. This donor performed up to 16 donations, which was an unusual case in CCP donor. The SARS-CoV-2 antibody titer was analyzed using Elecsys® Anti-SARS-CoV-2 (Roche Diagnostics). The SARS-CoV-2 antibody showed high level of total SARS-CoV-2 antibodies, with the Cut off Indexes (COI) anti SARS-Cov-2 antibody were still quite high (132 U/mL). The highest donor antibody COI (204.6 U/mL) was seen in 11th donation at 6 months after recovery, while the lowest antibody COI (130.8 U/mL) was in 15th donation at 7 months after recovering. Evaluation of donor health status were performed after the 16th donation and analyzed as well. In conclusion, 16 CCP donations of 600 mL resulting in 48 units of 200 mL plasma in 8 months was safe for the donor, with the SARS-Cov-2 antibody titer remained high in the whole period. |
| first_indexed | 2024-03-11T23:14:46Z |
| format | Article |
| id | doaj.art-b5687262347e419e9e4487b344340161 |
| institution | Directory Open Access Journal |
| issn | 2085-4145 2527-2950 |
| language | English |
| last_indexed | 2024-03-11T23:14:46Z |
| publishDate | 2023-08-01 |
| publisher | Faculty of Medicine |
| record_format | Article |
| series | JKKI (Jurnal Kedokteran dan Kesehatan Indonesia) |
| spelling | doaj.art-b5687262347e419e9e4487b3443401612023-09-21T04:54:28ZengFaculty of MedicineJKKI (Jurnal Kedokteran dan Kesehatan Indonesia)2085-41452527-29502023-08-0120320910.20885/JKKI.Vol14.Iss2.art1234997A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case reportTeguh Triyono0Usi Sukorini1Andri Christianalusi2Sri Mulatsih3Hans Vrielink4Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Sleman, IndonesiaFaculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Sleman, IndonesiaFaculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Sleman, IndonesiaFaculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Sleman, IndonesiaUniversity of Amsterdam, Amsterdam, NetherlandsCovid-19 Convalescent Plasma (CCP) was one of alternative therapy for Covid-19 patients. The use of convalescent plasma as an adjunct therapy must consider its efficacy, benefits, and risk, both for the patient and the donor. Convalescent Plasma was produced from purified human plasma. Convalescent Plasma was a passive immunity which provide active antibodies. CCP give immunity to the patient through the transfusion of a survivor’s antibodies. We were reporting a case of male CCP donor with long existence of SARS-Cov-2. This donor performed up to 16 donations, which was an unusual case in CCP donor. The SARS-CoV-2 antibody titer was analyzed using Elecsys® Anti-SARS-CoV-2 (Roche Diagnostics). The SARS-CoV-2 antibody showed high level of total SARS-CoV-2 antibodies, with the Cut off Indexes (COI) anti SARS-Cov-2 antibody were still quite high (132 U/mL). The highest donor antibody COI (204.6 U/mL) was seen in 11th donation at 6 months after recovery, while the lowest antibody COI (130.8 U/mL) was in 15th donation at 7 months after recovering. Evaluation of donor health status were performed after the 16th donation and analyzed as well. In conclusion, 16 CCP donations of 600 mL resulting in 48 units of 200 mL plasma in 8 months was safe for the donor, with the SARS-Cov-2 antibody titer remained high in the whole period.https://jurnal.uii.ac.id/JKKI/article/view/25589 |
| spellingShingle | Teguh Triyono Usi Sukorini Andri Christianalusi Sri Mulatsih Hans Vrielink A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report JKKI (Jurnal Kedokteran dan Kesehatan Indonesia) |
| title | A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report |
| title_full | A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report |
| title_fullStr | A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report |
| title_full_unstemmed | A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report |
| title_short | A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report |
| title_sort | male covid 19 convalescent plasma donor with long existence of sars cov 2 antibodies a case report |
| url | https://jurnal.uii.ac.id/JKKI/article/view/25589 |
| work_keys_str_mv | AT teguhtriyono amalecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT usisukorini amalecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT andrichristianalusi amalecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT srimulatsih amalecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT hansvrielink amalecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT teguhtriyono malecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT usisukorini malecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT andrichristianalusi malecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT srimulatsih malecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport AT hansvrielink malecovid19convalescentplasmadonorwithlongexistenceofsarscov2antibodiesacasereport |